Healthcare / Medical DistributionTaiwan
$34.70
+0.30 (+0.87%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 32% · confianza 25%
FCF escenarios
weak_data · normalized FCF $431.6M · quality 60.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
53/100
C
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$5.1B
P/E
14.6x
↓EV/EBITDA
8.9x
↓ROE
4.0%
↑Gross Margin
38.7%
↓Debt/Equity
0.39
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+0.4%
FCF CAGR
—
FCF margin
6.2%
FCF / Net income
1.76x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $8.57B · net income $300.1M · FCF $528.8M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $8.57B | $8.57B | $8.92B | $8.57B | $8.46B |
| Net Income | $300.1M | $300.1M | $317.3M | $322.3M | $477.5M |
| EBITDA | $828.1M | $828.1M | $804.9M | $765.0M | $922.4M |
| EPS | — | — | 2.48 | 2.16 | 3.20 |
| Gross Margin | 38.7% | 38.7% | 38.2% | 36.6% | 36.5% |
| Operating Margin | 5.0% | 5.0% | 3.4% | 2.8% | 4.4% |
| Net Margin | 3.5% | 3.5% | 3.6% | 3.8% | 5.6% |
| Balance Sheet | |||||
| Debt/Equity | 0.39 | 0.39 | 0.42 | 0.46 | 0.40 |
| Current Ratio | 1.45 | 1.45 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $528.8M | $528.8M | $431.6M | $339.8M | $-103.7M |
| Returns | |||||
| ROE | 4.0% | 4.0% | 4.2% | 4.3% | 6.5% |
| Valuation | |||||
| P/E | 14.58 | 14.58 | 14.90 | — | — |
| EV/EBITDA | 8.85 | 8.85 | 9.03 | — | — |
| P/B | 0.67 | 0.67 | 0.63 | — | — |
| Growth & Yield | |||||
| Revenue Growth | -3.9% | -3.9% | 4.0% | 1.4% | — |
| EPS Growth | — | — | 14.8% | -32.6% | — |
| Dividend Yield | 3.0% | 3.0% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-4.8%
Start / end P/E
n/dx → n/dx
EPS bridge
2.48 → n/d
Residual
-7.7%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.